News Center

位置：

Honors Announcement

Group News

Media Reports

Shijiazhuang Sihua Pharmaceutical Group Makes Its Debut at the 2026 Natural Products Expo West

Category:

Group News

发布时间：2026-03-09

【概要描述】 From March 4 to 6 local time, the 2026 Natural Products Expo West was held at the Anaheim Convention Center in California. The API export team of Shijiazhuang Sihua Pharmaceutical Group showcased its competitive, specialty API products at the exhibition, actively pursuing opportunities in the North American and global markets.

Shijiazhuang Sihua Pharmaceutical Group Makes Its Debut at the 2026 Natural Products Expo West

From March 4 to 6, local time, the 2026 Natural Products Expo West was held at the Anaheim Convention Center in California. The API export team of Shijiazhuang Sihua Pharmaceutical Group showcased its portfolio of premium, specialty APIs at the exhibition, actively pursuing market expansion in North America and globally.

As the largest and most influential event in North America’s natural health and functional ingredients industry, this exhibition brings together more than 3,300 premier companies from around the globe. It serves as a key showcase for cutting-edge technologies, high-end raw materials, and emerging health consumption trends, while also providing a central platform for premium ingredient suppliers to connect with international high-end distribution channels and expand into global markets.

At the exhibition, the Group’s spacious and open booth drew keen attention from professional visitors and international buyers at home and abroad. The API export team actively promoted the Company’s achievements in both bulk and specialty APIs to existing and new customers, while engaging in in-depth discussions and negotiations on cooperation for 2026. According to the Group’s API export staff, the Company has steadily intensified its “going global” strategy. Its flagship and competitive products—such as caffeine, azithromycin, theophylline, and metronidazole—have seen growing recognition in the food additives and pharmaceutical manufacturing sectors. In 2025, the Company successfully obtained the European Pharmacopoeia Certificate of Suitability (CEP) for its caffeine product, further enhancing brand influence and attracting widespread attention from markets in Europe, North America, South Asia, and Southeast Asia.

Guided by the innovation-driven development strategy, the Group is vigorously promoting the coordinated development of bulk active pharmaceutical ingredients (APIs) and specialty, high-end APIs, thereby driving the transformation of the API industry toward greater innovation and higher quality while precisely aligning with global market demand. To date, the Group has obtained approval for 96 API products, spanning multiple therapeutic areas including food additives, cardiovascular, respiratory, anti-infective, and central nervous system indications. The product portfolio is steadily maturing, further strengthening the Group’s core competitive advantages.

“The North American market is the most important end-market in the pharmaceutical APIs sector and sets the direction for industry development,” said the group’s head of API foreign trade. The company will closely align with international demand for API products, leveraging “innovation-driven growth and quality leadership” as its dual engines to continuously expand its presence in global markets, steadily enhance its level of international operations, and promote the entry of more high-quality products into the international marketplace.

Keywords:

Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Wins the “Leading Enterprise in Scientific and Technological Innovation” Award from the Cangzhou Lingang Economic Development Zone

Shijiazhuang Sihua Pharmaceutical has had 45 products across 55 specifications selected in the first through eighth rounds of national centralized procurement follow-up purchases.